Propylthiouracil-induced ANCA-positive erythema nodosum treated with thalidomide

Int J Dermatol. 2012 Mar;51(3):345-8. doi: 10.1111/j.1365-4632.2011.05135.x.

Abstract

Background: Propylthiouracil (PTU), one of the mainstays of antithyroid therapy drugs, can lead to antineutrophil cytoplasmic antibody (ANCA) positivity and skin lesions. PTU-induced ANCA-positive vasculitis is rare and even more rare is erythema nodosum.

Objective: To report a case of a 57-year-old woman with hyperthyroidism who developed myeloperoxidase (MPO)-ANCA erythema nodosum after PTU treatment for 11 months.

Methods: Skin biopsy demonstrated septal panniculitis without vasculitis. PTU-induced ANCA-positive erythema nodosum was made.

Results: With discontinuation of PTU and initiation of thalidomide, skin lesions resolved completely in three weeks, and after three months, the titers of MPO-ANCA and perinuclear-ANCA (p-ANCA) had decreased remarkably. At 14-month follow-up, the patient was asymptomatic, but low levels of ANCA titers persisted.

Conclusions: This report indicated that ANCA positive erythema nodosum could develop following PTU treatment. Thalidomide has been proven to be helpful and averted the adverse effects from systemic corticosteroids and other immunosuppressive drugs in this patient.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Antineutrophil Cytoplasmic / analysis*
  • Antithyroid Agents / adverse effects*
  • Antithyroid Agents / therapeutic use
  • Erythema Nodosum / chemically induced*
  • Erythema Nodosum / drug therapy*
  • Erythema Nodosum / immunology
  • Female
  • Humans
  • Hyperthyroidism / drug therapy
  • Immunologic Factors / therapeutic use*
  • Middle Aged
  • Propylthiouracil / adverse effects*
  • Propylthiouracil / therapeutic use
  • Thalidomide / therapeutic use*

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Antithyroid Agents
  • Immunologic Factors
  • Thalidomide
  • Propylthiouracil